FSII Stock Price, News & Analysis

FSII NASDAQ

Company Description

FSII (NASDAQ: FSII) is a publicly traded company.

FSII stock has declined 9.2% over the past year.

This page provides a comprehensive overview of FSII stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-9.18%

Performance 1 year

$0.0

Market Cap

20.7M

Shares outstanding

FSII (FSII) stock. Over the past 12 months, the stock has lost 9.2%.

Latest News

View All

December 21, 2021

-1.19%

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

acquisition covid-19

December 1, 2021

-0.61%

FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021

June 29, 2021

+1.13%

Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections

acquisition

February 17, 2021

+73.47%

FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offering

IPO offering

FSII has 4 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 2 with negative movement. Key topics include acquisition, covid-19, IPO, offering. View all FSII news →

SEC Filings

View All

No SEC filings available for FSII.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months